osimertinib
astrazeneca
['adaura', 'nsclc', 'sclc', 'osimertinib', 'aura ,(-laura)']
patients with resected, egfr-mutated, stage ib to iiia nsclc were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. full results of the adaura trial: #asco2023 #asco23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.